Rx00158 - Metyrosine


Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00158
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
lower respiratory tract infections grade IV, anaerobically infected, decubitus ulcers 8536 196704 15841 11.053 0 0.0
bone infections grade IV, anaerobically infected, decubitus ulcers 1776 3629 15841 124.655 0 0.0
Symptomatic Trichomoniasis symptomatic Trichomoniasis 2675 2675 2675 1508.383 0 0.0
skin infections grade IV, anaerobically infected, decubitus ulcers 745 4323 15841 43.896 0 0.0
bacterial septicemia grade IV, anaerobically infected, decubitus ulcers 2416 9413 15841 65.376 0 0.0
pustules of rosacea rosacea 4221 4221 4221 955.917 0 0.0
pneumonia grade IV, anaerobically infected, decubitus ulcers 4140 36519 15841 28.876 0 0.0
intra-abdominal abscess active perianal Crohn's disease 573 2053 11834 95.163 0 0.0
skin structure infections grade IV, anaerobically infected, decubitus ulcers 745 4323 15841 43.896 0 0.0
endocarditis grade IV, anaerobically infected, decubitus ulcers 327 2702 15841 30.826 0 0.0
Asymptomatic Trichomoniasis symptomatic Trichomoniasis 2675 2675 2675 1508.383 0 0.0
inflammatory lesions of rosacea rosacea 4221 4221 4221 955.917 0 0.0
inflammatory papules inflammatory pustules 3454 3454 3454 1168.189 0 0.0
empyema grade IV, anaerobically infected, decubitus ulcers 151 971 15841 39.611 1.27E-174 4.08e-171
peritonitis grade IV, anaerobically infected, decubitus ulcers 112 590 15841 48.352 8.49E-139 2.73e-135
Anaerobic Bacterial Infections grade IV, anaerobically infected, decubitus ulcers 87 324 15841 68.395 7.91E-120 2.54e-116
lung abscess grade IV, anaerobically infected, decubitus ulcers 66 487 15841 34.52 7.20E-74 2.31e-70
meningitis grade IV, anaerobically infected, decubitus ulcers 48 797 15841 15.34 8.56E-39 2.75e-35
liver abscess amebic liver abscess 10 590 18 3799.363 6.41E-32 2.06e-28
brain abscess grade IV, anaerobically infected, decubitus ulcers 17 185 15841 23.406 1.30E-17 4.18e-14

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
PNEUMONIA POUCHITIS 8.87e-07 CD14, IL1RN, NCF4, NOD2, TLR4, TLR9, TNF
PERITONITIS POUCHITIS 9.11e-06 CD14, IL1RN, NOD2, TNF

Chemical, Pharmacological and Biological Annotations


ATC Code:
C02KB01
Category:
Enzyme Inhibitors
PubChem ID:
441350
KEGG Drug ID:
D00762
SMILE:
C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O
InChI:
1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Phenylpropanoids and Polyketides
Class:
Phenylpropanoic Acids
Subclass:
Indication:
For use in the treatment of patients with pheochromocytoma, for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma.
Pharmacodynamics:
In patients with pheochromocytoma, who produce excessive amounts of norepinephrine and epinephrine, administration of one to four grams of metyrosine per day has reduced catecholamine biosynthesis from about 35 to 80 percent as measured by ...
Click to show more...
Description:
An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Phar...
Click to show more...
Mechanism:
Metyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, bloc...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
-
Caco-2 permeable:
-
P-glycoprotein substrate:
Substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.1516 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org